MDM2 and myelodysplastic syndrome: This drug has also been reported in 5q-MDS patients to result in increased survival and a reduced risk of transformation to AML [55], raising the possibility that one mechanism of action of lenalidomide is to inhibit GSK-3 phosphorylation of MDM2 and restore a normal p53 response to the acquisition of oncogenic mutations.